-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guidelines recommend cisplatin-based neoadjuvant chemotherapy, followed by radical cystectomy and pelvic lymphadenectomy, or organ-sparing chemoradiotherapy as standard therapy for muscle-invasive bladder cancer
guide
The NEOBLADE study was designed to evaluate the effect of adding the small molecule tyrosine kinase inhibitor nintedanib to neoadjuvant chemotherapy on response rates and survival outcomes in patients with muscle-invasive bladder cancer
The study is a parallel-arm, double-blind, randomized, placebo-controlled Phase 2 clinical trial recruiting patients 18 years of age and older with locally advanced muscle-invasive bladder cancer with an ECOG performance status of 0-1, randomized 1: 1 Divided into two groups, in addition to gemcitabine and cisplatin neoadjuvant chemotherapy plus nintedanib (150 mg or 200 mg, 2 / day, for 12 weeks) or placebo
The median follow-up was 33.
thrombotic myocardial infarction
In conclusion, for patients with muscle-invasive bladder cancer, the addition of nintedanib to the standard chemotherapy regimen is safe, but does not significantly improve the rate of pathological complete response
For patients with muscle-invasive bladder cancer, the addition of nintedanib to the standard chemotherapy regimen is safe, but does not significantly improve the rate of pathological complete response
Original source:
Syed A Hussain, et al.
leave a message here